 |
|
More insight into Alzheimer's disease with Stanford discovery of possible cause
November 21, 2006STANFORD, Calif.-A peacekeeper in the body's defenses against infection may hold the key to understanding-and eventually treating-Alzheimer's disease. Researchers at the Stanford University School of Medicine discovered that when a molecule responsible for dialing down the immune system malfunctions in the brain cells of mice, the rodents develop symptoms of the degenerative brain disease.
The finding, published in the November issue of the Journal of Clinical Investigation, offers researchers an insight into how humans may develop Alzheimer's, said the study's senior author Tony Wyss-Coray, PhD, associate professor of neurology and a researcher at the Veterans Affairs Palo Alto Health Care System.
Alzheimer's disease is characterized by an excessive buildup of proteins into plaques and tangles of cellular gunk that are likely to cause brain cells to die and lose their connections to other neurons. But for the most part, scientists do not understand the underlying biological problems behind Alzheimer's, making it difficult for doctors to treat, let alone cure.
"We don't have a treatment that alters the course of the disease," said Wyss-Coray.
Wyss-Coray and Ina Tesseur, PhD, an instructor in the Department of Neurology, examined thin slices of the brains of Alzheimer's patients who had died, and discovered abnormally low levels of a molecule involved in controlling the body's response to infection. That molecule allows the brain to detect and respond to TGF-beta, or transforming growth factor, a protein teeming through our bodies, involved in fighting infection, stopping cancer and perhaps keeping brain cells alive.
No other researchers had seen this change before, so Tesseur and Wyss-Coray set out to investigate whether it had some connection to Alzheimer's disease. They hypothesized that by protecting neurons, TGF-beta may help prevent Alzheimer's disease. If the TGF-beta pathway is turned off, the brain becomes more susceptible to a toxic buildup of proteins.
"We tried to see what happens if we block neurons from getting this beneficial signal," said Wyss-Coray.
To investigate that hypothesis, the researchers genetically engineered mice with a defect similar to the one they found in the brains of Alzheimer's patients: These mice had brain cells that could no longer respond to TGF-beta's salutary signal.
The mutation did not directly affect the TGF-beta protein, which is found throughout the body. Instead, it blocked brain cells' ability to detect and respond to the molecule. This way, the TGF-beta pathway was active everywhere else besides the neurons of the mice.
Unable to receive the beneficial TGF-beta signal, the rodents with the broken pathway showed signs of Alzheimer's disease. Brain cells died as the mice grew older, and the cells failed to make connections to other brain cells, a defining trait of the cells.
The results were even more striking when the researchers blocked the TGF-beta pathway in mice that were already susceptible to an Alzheimer's-like disease. These mice had a rare version of a human gene that causes people to develop Alzheimer's in their 40s and 50s, said Wyss-Coray. Blocking TGF-beta in these mice caused the animals to display signs of Alzheimer's disease that researchers had until then failed to recreate. The brains of the mice had more dead cells and a protein buildup characteristic of the disease in humans.
"Our study offers the possibility that if you have a reduction in this pathway, then you can accelerate the pathology," said Wyss-Coray. The flip side is that activating the TGF-beta pathway may offer a treatment for Alzheimer's, he said.
In the past, researchers have tried using molecules that work like TGF-beta to provide protection against Alzheimer's, but they had trouble getting them into the brain, said Wyss-Coray. Those proteins, or the cells used to carry them, are too large to enter the brain through the bloodstream.
To sidestep that problem, Wyss-Coray is working with chemists to identify small molecules-drugs-that can boost the TGF-beta pathway in neurons. Because of TGF-beta's many roles in the body, Wyss-Coray will also be searching for molecules that act only on brain cells. He will test whether these drugs can ameliorate the Alzheimer's-like disease he created in mice.
Wyss-Coray said that for now the strategy is "wishful thinking," but based on the results of this study, it's worth trying.
Stanford University Medical Center
"We don't have a treatment that alters the course of the disease," said Wyss-Coray.
Wyss-Coray and Ina Tesseur, PhD, an instructor in the Department of Neurology, examined thin slices of the brains of Alzheimer's patients who had died, and discovered abnormally low levels of a molecule involved in controlling the body's response to infection. That molecule allows the brain to detect and respond to TGF-beta, or transforming growth factor, a protein teeming through our bodies, involved in fighting infection, stopping cancer and perhaps keeping brain cells alive.
No other researchers had seen this change before, so Tesseur and Wyss-Coray set out to investigate whether it had some connection to Alzheimer's disease. They hypothesized that by protecting neurons, TGF-beta may help prevent Alzheimer's disease. If the TGF-beta pathway is turned off, the brain becomes more susceptible to a toxic buildup of proteins.
"We tried to see what happens if we block neurons from getting this beneficial signal," said Wyss-Coray.
To investigate that hypothesis, the researchers genetically engineered mice with a defect similar to the one they found in the brains of Alzheimer's patients: These mice had brain cells that could no longer respond to TGF-beta's salutary signal.
The mutation did not directly affect the TGF-beta protein, which is found throughout the body. Instead, it blocked brain cells' ability to detect and respond to the molecule. This way, the TGF-beta pathway was active everywhere else besides the neurons of the mice.
Unable to receive the beneficial TGF-beta signal, the rodents with the broken pathway showed signs of Alzheimer's disease. Brain cells died as the mice grew older, and the cells failed to make connections to other brain cells, a defining trait of the cells.
The results were even more striking when the researchers blocked the TGF-beta pathway in mice that were already susceptible to an Alzheimer's-like disease. These mice had a rare version of a human gene that causes people to develop Alzheimer's in their 40s and 50s, said Wyss-Coray. Blocking TGF-beta in these mice caused the animals to display signs of Alzheimer's disease that researchers had until then failed to recreate. The brains of the mice had more dead cells and a protein buildup characteristic of the disease in humans.
"Our study offers the possibility that if you have a reduction in this pathway, then you can accelerate the pathology," said Wyss-Coray. The flip side is that activating the TGF-beta pathway may offer a treatment for Alzheimer's, he said.
In the past, researchers have tried using molecules that work like TGF-beta to provide protection against Alzheimer's, but they had trouble getting them into the brain, said Wyss-Coray. Those proteins, or the cells used to carry them, are too large to enter the brain through the bloodstream.
To sidestep that problem, Wyss-Coray is working with chemists to identify small molecules-drugs-that can boost the TGF-beta pathway in neurons. Because of TGF-beta's many roles in the body, Wyss-Coray will also be searching for molecules that act only on brain cells. He will test whether these drugs can ameliorate the Alzheimer's-like disease he created in mice.
Wyss-Coray said that for now the strategy is "wishful thinking," but based on the results of this study, it's worth trying.
Stanford University Medical Center
Alzheimers Disease Current Events and Alzheimers Disease News RSSCold sore virus might play role in Alzheimer's disease
A gene known to be a major risk factor for Alzheimer's disease puts out the welcome mat for the virus that causes cold sores, allowing the virus to be more active in the brain compared to other forms of the gene.
Study offers window into human behavior, brain disease
UCSF scientists have identified a cell population that is a primary target of the degenerative brain disease known as frontotemporal dementia, which is as common as Alzheimer's disease in patients who develop dementia before age 65.
New imaging compound might 'see' Alzheimer's earlier
A new imaging molecule that can detect and map plaques and tangles in the brains of people with Alzheimer's disease could eventually lead to earlier diagnosis of the devastating disease, researchers at the University of California, Los Angeles report in the Dec. 21, 2006, issue of the New England Journal of Medicine.
Testosterone therapy may prevent Alzheimer's disease
Researchers at the University of Southern California have discovered a direct link between loss of testosterone and the development of an Alzheimer's-like disease in mice. They also discovered that testosterone treatment slows progression of the disease.
Androgen therapy may slow progress of Alzheimer's disease
Experiments on mouse models of Alzheimer's disease (AD) suggest that treatment with male sex hormones might slow its progression.
Protein 'fingerprint' in spinal fluid could spot Alzheimer's disease
Scientists collaborating at Cornell University in Ithaca and Weill Cornell Medical College in New York City have identified a panel of 23 protein biomarkers in cerebrospinal fluid that acts as a neurochemical "fingerprint," which doctors might use someday to identify patients living with Alzheimer's disease.
Study shows cats can succumb to feline Alzheimer's disease
Ageing cats can develop a feline form of Alzheimer's disease, a new study reveals. Scientists at the Universities of Edinburgh, St Andrews, Bristol and California have identified a key protein which can build up in the nerve cells of a cat's brain and cause mental deterioration.
Scientists develop a new way to target Alzheimer's disease
The pathological embrace between two proteins plays a key role in the development of Alzheimer's disease by triggering the formation of neuron-killing plaques of amyloid beta protein. Now a group of scientists at NYU School of Medicine have devised a way to reduce amyloid beta deposition by interfering with the deadly embrace of these proteins.
Complaints About Memory Are Associated With Alzheimer-Related Brain Damage
Researchers at Rush University Medical Center found that having complaints about memory problems is associated with changes in the brain related to Alzheimer's disease. They reported their findings in the November 2006 issue of Neurology.
Yeast model shows promise as Alzheimer's test
A century ago this month, German psychiatrist Alois Alzheimer formally described characteristics of the neurodegenerative disease which ultimately came to bear his name.
More Alzheimers Disease Current Events and Alzheimers Disease News Articles
 | A Caregiver's Guide to Alzheimer's Disease: 300 Tips for Making Life Easier An estimated 5 million Americans have Alzheimer's disease. That number continues to grow — by 2050 the number of individuals with Alzheimer's could range from 11.3 million to 16 million. Alzheimer's disease is not a normal part of aging. It is a devastating disorder of the brain's nerve cells that impairs memory, thinking, and behavior. Winner of the 2006 American Journal of Nursing Book of... |
 | Mayo Clinic on Alzheimer's Disease by Ronald Peterson M.D. Mayo Clinic, Rochester, MN. Consumer text covers how the brain functions and what can go wrong, conditions causing dementia, conditions that may accompany Alzheimer's, theories about causes, treatment of symptoms, tips for daily caregiving, care arrangements, and care costs.... |
 | Alzheimer's Disease: A Guide for Families and Caregivers by Lenore Powell, Katie Courtice, Ed.D. Lenore Powell, Katie Courtice When people suffer from Alzheimer's disease, their family and friends usually must care for them and make decisions on their behalf, tasks that can be emotionally and physically draining. Backed by solid medical information about the specifics of the disease-from early signs, testing, and diagnosis to treatments and long-term care-this comprehensive guide will help family and caregivers alike be... |
 | Alzheimer's Disease & the Dementias: An Alternative Perspective : Based on the Readings of Edgar Cayce (Edgar Cayce Health) by David McMillin |
| He Used to Be Somebody, 1995: A Journey into Alzheimer's Disease Through the Eyes of a Caregiver by Beverly Bigtree Murphy This book is one of the best case histories of Alzheimer's Disease that you will find and it is the only book about home care of an Alzheimer's family member available today. There are 4 million people currently with this illness, 80% of them are cared for at home. Thomas V. Murphy struggled for 14 years with this illness and was maintained in his home by his wife, Beverly, until he died. ... | |
 | Alzheimer's Disease & Related Dementias: A Guidebook for Care, Comfort, Legal and Financial Security by The Center for Elder Law, Home Instead Senior Care A guidebook for those serving as caregivers to those with Alzheimer's disease and other related dementias. Section Titles Include: What is Alzheimer's and Dementia?; Medicaid Basics; What is a Will, and How Does a Will Work; Revocable Living Trust: What You Need to Know; Durable Power of Attorney & Elder Law Power of Attorney; Improved Pension Benefits for Veterans and Their Spouses; What... |
 | Alzheimer's Disease: The Family Journey by Wayne A. Caron, James J. Pattee, Orlo J. Otteson This is a book for lay people - those who live with Alzheimer's in their family. The book focuses on family relations as impacted by the illness and as a source for strength and coping. The book helps readers navigate through the experiences of dementia with the help of a phase model of Alzheimer's - a map which describes the common challenges faced by families from the very first symptoms to the... |
 | Alzheimer's Disease: Caregivers Speak Out by Pam Haisman "Alzheimer's Disease: Caregivers Speak Out" is a guide for families, friends,professionals and students to better understanding those who have Alzheimer's disease and the people who care for them. Through their own heartfelt words and experiences, caregivers share feelings and ideas in an effort to teach others about this disease. Caregivers say they wish this had been the first book they had... |
 | Learning to Speak Alzheimer's: A Groundbreaking Approach for Everyone Dealing with the Disease by Joanne Koenig Coste More than four million Americans suffer from Alzheimer's, and as many as twenty million have close relatives or friends with the disease. Revolutionizing the way we perceive and live with Alzheimer's, Joanne Koenig Coste offers a practical approach to the emotional well-being of both patients and caregivers that emphasizes relating to patients in their own reality. Her accessible and... |
| Mayo Clinic Guide to Alzheimer's Disease The essential resource for treatment, coping and caregiving for... |
| © 2008 BrightSurf.com |